This issue of Emerging Cancer Therapeutics provides a comprehensive review for practitioners on the current status of lung cancer treatment. Lung cancer treatment has undergone major changes over the course of the past few years and the pace of new research and development is expected to continue at a high level for the immediate future. Lung Cancer addresses current best practices in the light of the most recent evidence and new developments in this field. All of the chapters are written by international experts in the field, address the common clinical scenarios in Lung cancer and are multidisciplinary in scope. Coverage includes discussion of prevention, screening, surgery, radiation therapy, chemotherapy, immunotherapy, new therapeutic approaches, and more.(15) that evaluated gemcitabine maintenance. In their study, PS 2 2 was found as a prognostic factor for survival in the overall multivariate analysis (HR = 1.5; P = . 009) (15). In contrast, all positive trials such as JMEN, SATURN, and the mostanbsp;...
|Publisher||:||Demos Medical Publishing - 2012-05-18|